Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer

被引：0
|
作者：
Antonarakis, Emmanuel S. [1 ]
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Oncol & Urol, Baltimore, MD 21287 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：316 / 319
页数：4
相关论文
共 50 条
  • [21] Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer
    Lai, Lillian Y.
    Oerline, Mary K.
    Caram, Megan E., V
    Tsao, Phoebe A.
    Kaufman, Samuel R.
    Hollenbeck, Brent K.
    Shahinian, Vahakn B.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (08): : 1127 - 1134
  • [22] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [23] Caffeic acid phenethyl ester suppresses drug resistance of enzalutamide or abiraterone in prostate cancer cells
    Chuu, Chih-Pin
    Kuo, Ying-Yu
    Huo, Chieh
    ANNALS OF ONCOLOGY, 2022, 33 : S493 - S494
  • [24] Re: Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2020, 203 (04): : 662 - 663
  • [25] Re:Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
    Rubio-Briones, Jose
    EUROPEAN UROLOGY, 2020, 77 (04) : 560 - 561
  • [26] Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone.
    Scholz, Mark Creamer
    Lam, Richard Y.
    Turner, Jeffrey S.
    Chau, Khang N.
    Becker, Lauren K.
    Felarca, Clifford U.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
    Mori, Keiichiro
    Egawa, Shin
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2020, 77 (06) : 758 - 759
  • [28] Management of locally advanced prostate cancer before the era of abiraterone/enzalutamide: A case study from India
    Rawal, Sudhir
    PROSTATE INTERNATIONAL, 2015, 3 : 520 - 521
  • [29] Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
    Shah, Yash B.
    Shaver, Amy L.
    Beiriger, Jacob
    Mehta, Sagar
    Nikita, Nikita
    Kelly, William Kevin
    Freedland, Stephen J.
    Lu-Yao, Grace
    CANCERS, 2022, 14 (15)
  • [30] Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
    Simon, Iris
    Perales, Sonia
    Casado-Medina, Laura
    Rodriguez-Martinez, Alba
    del Carmen Garrido-Navas, Maria
    Puche-Sanz, Ignacio
    Diaz-Mochon, Juan J.
    Alaminos, Clara
    Lupianez, Pablo
    Lorente, Jose A.
    Serrano, Maria J.
    Real, Pedro J.
    CANCERS, 2021, 13 (06) : 1 - 21
12345